ORPH.L Regulatory News (ORPH)

Announcement to be made by the Euronext Growth Applicant prior to admission in accordance with rule 2 of the Euronext Growth Rules for Companies

Company name

Venn Life Sciences Holdings plc

Company registered address and if different, company trading address (including postcodes)

Registered Office:

PO Box W1J 6BD, Berkley Square House, 2nd Floor, Mayfair, London, W1J 8DJ

Trading Office:

19 Railway Road, Dalkey, Dublin, Ireland

Country of incorporation  

England and Wales

Company website address containing all information required by rule 26 in the Euronext Growth Rules for Companies

www.vennlifesciences.com/ and with effect from Admission, www.openorphan.com

Company business (including main country of operation) or, in the case of an investing company, details of its investing strategy. If the admission is sought as a result of a reverse takeover under rule 14 of the Euronext Growth Rules for Companies, this should be stated

This is a reverse takeover under Rule 14.

Open Orphan is Clinical Research Organisation that specialises in rare and orphan drugs. The headquarters are in Dublin, Ireland and the company also has offices in France, the Netherlands and Germany.

Details of securities to be admitted including any restrictions as to transfer of securities (i.e. where known, number of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

Number of ordinary shares of 0.01 pence each in nominal value ("Ordinary Shares") for which Admission will be sought: 253,493,259

Placing price per Ordinary Share: 5.6 pence

The are no restrictions as to the transferability of the Ordinary Shares and no Ordinary Shares will be held in treasury.

Capital to be raised on admission (if applicable) and anticipated market capitalisation on admission:

Capital to be raised on admission: £4.5m (€5.0m)

Anticipated market capitalisation on admission: £14.1m (€15.8m)

Percentage of Euronext Growth securities not in public hands on admission

Approximately 31.1%

Details of any other exchange or trading platform to which the ex securities (or other securities of the company) are or will be admitted or traded:

AIM

Full names and functions of directors and proposed directors (underlining the first name by which each is known or including any other name by which each is known):

Directors:

Brendan Buckley, Non-executive Chairman

Cathal Friel, Chief Executive Officer

Christian Milla, Chief Operating Officer

Tony Richardson, Corporate Development Officer

Michael Ryan, Senior non-executive Director

Proposed Director:

Maurice Treacy, Executive Director

Full names and holdings of significant shareholders, expressed as a percentage of the issued share capital, before or after admission (underlining the first name by which each is known or including any other name by which each is known):

Before Admission

After Admission

Names of all persons to be disclosed in accordance with schedule two, paragraph (h) of the Euronext Growth Rules for Companies:

n/a

i anticipated accounting reference date : 31 December

ii date to which the main financial information in the admission document has been prepared: 31 December 2018

iii. dates by which it must publish its first three reports pursuant to Rules 18 and 19 in the Euronext Growth Rules for Companies: 30 June 2019 due September 2019, 31 December 2019 due 30 June 2020, 30 June 2020 due September 2020

Expected admission date:

28 June 2019

Name and address of Euronext Growth Advisor

Davy Corporate Finance, Davy House, 49 Dawson Street, Dublin 2

Name and address of broker

Arden Partners plc., 125 Old Broad Street, London, EC2N 1AR

Other than in the case of a quoted Applicant, details of where (postal or internet address) the admission document will be available from, with a statement that this will contain full details about the Applicant and the admission of its securities

A copy of the admission document containing full details about the applicant and the admission of its securities will be available on the Company's website, www.vennlifesciences.com

Date of notification

14 June 2019

New/update: New